REG - Iconic Labs PLC - Result of AGM

Iconic LabsAnnouncement

13/02/2024 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240213:nRSM0017Da&default-theme=true

RNS Number : 0017D  Iconic Labs PLC  13 February 2024

13 February 2024

Iconic Labs PLC

("Iconic" or the "Company")

Result of AGM

Iconic Labs PLC (LSE: ICON) is pleased to announce that at the Company's
Annual General Meeting ('AGM') held earlier today, Resolutions 1 to 10 were
all duly approved by shareholders by way of a poll.

At the meeting, inter alia, a resolution was passed which approved the
sub-division and conversion of each existing ordinary share of £0.10
("Existing Ordinary Shares") into one new ordinary share of £0.0001  (a "New
Ordinary Share") and one deferred share of £0.0999 (a "Deferred Share") (each
such Deferred Share having no voting or dividend rights and effectively being
worthless) in order that the nominal value of a New Ordinary Share is less
than the price of a share in the market.

As a result, the Company's issued share capital will consist of 11,161,483
ordinary shares of £0.0001 each with one voting right (and deferred shares
of £0.0999 each with limited rights and which will not be admitted to
trading). Admission in respect of such New Ordinary Shares will become
effective and that dealings in those New Ordinary Shares will commence on 14
February 2024.

The above figure of 11,161,483 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

The results of the poll were as follows:

 

     Resolutions                                                                   For        %      Against  %     Withheld
 1   To receive and adopt the accounts for the financial year ended 30 June 2023.  3,374,840  99.19  27,718   0.81  4,837
 2   To re-appoint RPG Chartered Accountants as Auditors.                          3,369,888  99.17  28,070   0.83  9,437
 3   To authorise the Directors to determine the remuneration of the Auditors.     3,369,670  99.03  32,888   0.97  4,837

 4   To re-appoint Bradley Tyler Taylor as a Director.                             3,205,262  94.20  197,226  5.80  4,907
 5   To re-appoint Bela Lendvai-Lintner as a Director.                             3,206,467  94.24  196,021  5.76  4,907
 6   To re-appoint Victor Humberdot as a Director.                                 3,206,467  94.24  196,021  5.76  4,907
 7   To authorise the Directors to allot shares up to a maximum aggregate nominal  3,193,245  94.06  201,631  5.94  12,519
     amount of £4,668,047.83.
     Special Resolutions:
 8   To empower the Directors to generally allot relevant equity securities.       3,193,597  94.07  201,279  5.93  12,519
 9   Issued ordinary share capital be sub-divided and converted into one New       3,192,372  93.91  207,104  6.10  7,919
     Ordinary Share of £0.0001 and one Deferred Share of £0.0999.
 10  To authorise the Directors to make market purchases of own shares.            3,371,803  99.19  27,673   0.81  7,919

 

 

 

- Ends -

 

For more information, please contact:

 Iconic Labs                            Tel: +44 (0) 7462 156238

 Brad Taylor, Chief Executive Officer
 Novum Securities Limited               Tel: +44 (0) 20 7399 9400

 David Coffman / Daniel Harris
 Yellow Jersey PR                       Tel: +44 (0) 20 3004 9512

 Sarah Hollins                          iconic@yellowjerseypr.com

 Annabelle Wills

 Bessie Elliot

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPUAAPUPCGPW